HanssonGK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005; 352: 1685–95.
2.
LibbyPRidkerPMHanssonGK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009; 54: 2129–38.
3.
RidkerPMLüscherTF. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J. 2014; 35: 1782–91.
4.
WolfDLeyK. Immunity and Inflammation in Atherosclerosis. Circ Res. 2019; 124: 315–27.
5.
LeungYYYao HuiLL, et al.Colchicine--Update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015; 45:341–50.
6.
TapoiL BLSiriopolDKanbayMCovicA. Colchicine Use In Acute Coronary Syndromes: An Update. Angiology. 2021; 72(6):503–510.
7.
CrittendenDBLehmannRASchneckL, et al.Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J Rheumatol. 2012;39:1458–64
8.
VaidyaKTuckerBKurupR, et al.Colchicine Inhibits Neutrophil Extracellular Trap Formation in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention. J Am Heart Assoc. 2021; 10: e018993
9.
TardifJCKouzSWatersDD, et al.Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019; 381: 2497–505.
10.
ShahBPillingerMZhongH, et al.Effects of Acute Colchicine Administration Prior to Percutaneous Coronary Intervention: COLCHICINE-PCI Randomized Trial. Circ Cardiovasc Interv. 2020; 13: e008717.
11.
TongDCQuinnSNasisA, et al.Colchicine in Patients With Acute Coronary Syndrome: The Australian COPS Randomized Clinical Trial. Circulation. 2020; 142: 1890–900.
12.
NidorfSMEikelboomJWBudgeonCAThompsonPL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013; 61: 404–10.
13.
NidorfSMFioletATLMosterdA, et al.Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020; 383: 1838–47.
